On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Accadis Hochschule Bad Homburg

InstitutionResearch output, impact & collaborations

Accadis Hochschule Bad Homburg is a institution indexed in ScholarIQ from OpenAlex.

What is known about Accadis Hochschule Bad Homburg?

ScholarIQrecord summary

Accadis Hochschule Bad Homburg is a research organisation in Bad Homburg, DE. OpenAlex records 1,362 works and 9,874 citations for it. 329 researchers list it as their most recent affiliation.

How many works does Accadis Hochschule Bad Homburg have?

ScholarIQindexed works

Accadis Hochschule Bad Homburg has 1,362 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Accadis Hochschule Bad Homburg have?

ScholarIQcitation count

Accadis Hochschule Bad Homburg has 9,874 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Accadis Hochschule Bad Homburg?

ScholarIQresearcher count

Accadis Hochschule Bad Homburg has 329 researchers in the ScholarIQ index.

What is the average h-index at Accadis Hochschule Bad Homburg?

ScholarIQavg h-index

Accadis Hochschule Bad Homburg has an average h-index of 47 in OpenAlex.

What is the ROR of Accadis Hochschule Bad Homburg?

ScholarIQror

The ROR for Accadis Hochschule Bad Homburg is on the source record.

What is the OpenAlex record for Accadis Hochschule Bad Homburg?

ScholarIQopenalex

The OpenAlex for Accadis Hochschule Bad Homburg is on the source record.

Who are the most-cited researchers behind Accadis Hochschule Bad Homburg?

ScholarIQtop researchers by citations
1
Axel Haupt · Diabetes Treatment and Management
186 works11,031 citations

What are the most-cited papers on Accadis Hochschule Bad Homburg?

ScholarIQmost cited works
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Miličević, Mark L. Hartman
New England Journal of Medicine. 20231,028 Citations
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L. Hartman, Eric Lawitz, Raj Vuppalanchi, Jérôme Boursier, Elisabetta Bugianesi, Masato Yoneda, Cynthia Behling, Oscar W. Cummings, Yuanyuan Tang, Bram Brouwers, Deborah A. Robins, Amir Nikooie, Mathijs C. Bunck, Axel Haupt, Arun J. Sanyal
New England Journal of Medicine. 2024850 Citations
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Jorge Alsina‐Fernandez, Shweta Urva, Krister Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles Benson, Ruth E. Gimeno, David A. D’Alessio, Axel Haupt
Molecular Metabolism. 2018847 CitationsOPEN ACCESS
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E. Gimeno, Zvonko Miličević, Deborah A. Robins, Axel Haupt
The Lancet. 2018810 Citations
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, Julio Rosenstock, Sohini Raha, Rong Liu, Xiaosu Ma, Kieren J. Mather, Axel Haupt, Deborah A. Robins, Edward Pratt, Christof Kazda, Маниге Кониг
New England Journal of Medicine. 2023431 Citations

How much of the research on Accadis Hochschule Bad Homburg is open access?

ScholarIQopen access share
55%OPEN ACCESS
Gold
9%
Green
9%
Hybrid
18%
Bronze
18%
Closed
45%

Related on ScholarIQ

470M+ articles · 14-day free trial